3 teams in IRBLleida's cancer research receive funding from La Marató 2018
The head of the Cellular Signaling Group for Calcium, Carles Cantí, the head of the Oncology Pathology group, Xavier Matias-Guiu, and the Vice Rector for Students and Employability at the University of Lleida, Montse Rué
Three cancer research teams from the Lleida Biomedical Research Institute (IRBLleida) will receive funding from the Marató de TV3 and Catalunya Ràdio to carry out a three-year project to increase the quality and life expectancy of people with cancer. These are the projects presented by the head of the Calcium cellular signalling Group, Carles Cantí, the head of the Oncology Pathology Group, Xavier Matias-Guiu, and the Vice Chancellor for Students and Employability of the University of Lleida, Montse Rué.
Cantí, who will lead the project, has been awarded the project entitled "Targeting calcium channels against primary and resistant glioblastoma". Meanwhile, Matias-Guiu participates in a project led by the Vall de Hebron Institute of Oncology (VHIO) entitled "Personalized immunotherapy for endometrial cancer. Montse Rué also participates in a project led by the Vall de Hebron Institute of Oncology (VHIO) entitled "Liquid Biopsies for the identification of mechanisms of resistance PARP tone inhibitors in BRCA1 / 2- associated cancers." In total, IRBLleida research professionals will receive approximately € 350,000 with funding from La Marató.
The Calcium cellular signalling Group is one of the beneficiaries of the Marató 2018